Abstract
Autosomal dominant retinitis pigmentosa (ADRP) is frequently caused by mutations within the gene for the opsin of rod photoreceptor cells. Studies on transgenic mice, carrying mutated rhodopsin (RHO) transgene on different genetic backgrounds, suggested that an increased amount of wild-type RHO in ADRP photoreceptors attenuated the impact of the mutant transgene. Therefore, we employed a gene therapy approach with the help of Adeno-associated virus (AAV) to treat mice expressing a P23H mutant human RHO transgene. Knowing that AAV5 primarily transduces photoreceptor cells, we designed “hardened” form of the rhodopsin gene (RHO301) that expressed normal rhodopsin and was specifically resistant to degradation by the previously tested siRNA301. AAV5 RHO301 was subretinaly injected into the right eyes of P23H RHO mice at postnatal day 15. Animals were analyzed monthly by electroretinography (ERG) for 6 months. Analysis of the full-field scotopic electroretinogram (ERG) demonstrated that increased expression of opsin slowed the rate of retinal degeneration in P23H mice with increased amplitudes in both a-wave and b-wave amplitudes compared to control eyes. An increase in the ERG amplitudes was correlated with improvement of retinal structure. The thickness of the outer nuclear layer in AAV-RHO301-injected eyes was increased by 80% compared to control eyes. This finding indicates that wild-type RHO could rescue the retinal degeneration in transgenic mice carrying a dominant RHO mutation and that increased production of normal rhodopsin could suppress the effect of the mutant protein. These findings suggest that wild-type RHO can be used as a therapeutic agent to retard retinal degeneration in ADRP caused by different mutations of RHO via increased production of normal rhodopsin protein.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Bainbridge JWB, Smith AJ, Barker SS et al (2008) Effect of gene therapy on visual function in Leber’s congenital amaurosis. N Engl J Med 358:2231–2239
Bush RA, Kononen L, Machida S et al (2000) The effect of calcium channel blocker diltiazem on photoreceptor degeneration in the rhodopsin Pro23His rat. Invest Ophthalmol Vis Sci 41:2697–2701
Cashman SM, Binkley EA, Kumar-Singh R (2005) Towards mutation-independent silencing of genes involved in retinal degeneration by RNA interference. Gene Ther 12:1223–1228
Cideciyan AV, Hauswirth WW, Aleman TS et al (2009) Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year. Hum Gene Ther 20:999-1004
Daiger SP, Bowne SJ, Sullivan LS (2007) Perspective on genes and mutations causing retinitis pigmentosa. Arch Ophthalmol 125:151–158
Dryja TP, McGee TL, Reichel E et al (1990) A point mutation of the rhodopsin gene in one form of retinitis pigmentosa. Nature 343:364–366
Farrar GJ, Kenna PF, Humphries P (2002) On the genetics of retinitis pigmentosa and on mutation-independent approaches to therapeutic intervention. EMBO J 21:857–864
Frederick JM, Krasnoperova NV, Hoffmann K et al (2001) Mutant rhodopsin transgene expression on a null background. Invest Ophthalmol Vis Sci 42:826–833
Galy A, Roux MJ, Sahel JA et al (2005) Rhodopsin maturation defects induce photoreceptor death by apoptosis: a fly model for RhodopsinPro23His human retinitis pigmentosa. Hum Mol Genet 14:2547–2557
Georgiadis A, Tschernutter M, Bainbridge JW et al (2010) AAV-mediated knockdown of peripherin-2 in vivo using miRNA-based hairpins. Gene Ther 17:486–493
Gorbatyuk M, Justilien V, Liu J et al (2007a) Preservation of photoreceptor morphology P23H rats using an allele independent and function in ribozyme. Exp Eye Res 84:44–52
Gorbatyuk M, Justilien V, Liu J et al (2007b) Suppression of mouse rhodopsin expression in vivo by AAV mediated siRNA delivery. Vis Res 47:1202–1208
Gorbatyuk MS, Hauswirth WW, Lewin AS (2008) Gene therapy for mouse models of ADRP. Adv Exp Med Biol 613:107–112
Gorbatyuk MS, Timmers AMM, Pang JJ et al (2005a) Rescue of vision in P23H rats with an rAAV delivered ribozyme targeting mouse opsin. Invest Ophthalmol Vis Sci 46
Gorbatyuk MS, Pang JJ, Thomas J et al (2005b) Knockdown of wild-type mouse rhodopsin using an AAV vectored ribozyme as part of an RNA replacement approach. Mol Vis 11:648–656
Hartong DT, Berson EL, Dryja TP (2006) Retinitis pigmentosa. Lancet 368:1795–1809
Kiang AS, Palfi A, Ader M et al (2005) Toward a gene therapy for dominant disease: validation of an RNA interference-based mutation-independent approach. Mol Ther 12:555–561
Lewin AS, Drenser KA, Hauswirth WW et al (1998) Ribozyme rescue of photoreceptor cells in a transgenic rat model of autosomal dominant retinitis pigmentosa. Nat Med 4:967–971
Mendes HF, van der Spuy J, Chapple JP et al (2005) Mechanisms of cell death in rhodopsin retinitis pigmentosa: implications for therapy. Trends Mol Med 11:177–185
Olsson JE, Gordon JW, Pawlyk BS et al (1992) Transgenic mice with a rhodopsin mutation (Pro23His): a mouse model of autosomal dominant retinitis pigmentosa. Neuron 9:815–830
Organisciak DT, Darrow RM, Barsalou L et al (2003) Susceptibility to retinal light damage in transgenic rats with rhodopsin mutations. Invest Ophthalmol Vis Sci 44:486–492
Ranchon I, LaVail MM, Kotake Y et al (2003) Free radical trap phenyl-N-tert-butylnitrone protects against light damage but does not rescue P23H and S334ter rhodopsin transgenic rats from inherited retinal degeneration. J Neurosci 23:6050–6057
Roof DJ, Adamian M, Hayes A (1994) Rhodopsin accumulation at abnormal sites in retinas of mice with a human P23H rhodopsin transgene. Invest Ophthalmol Vis Sci 35:4049–4062
Simonelli F, Maguire AM, Testa F et al (2010) Gene Therapy for Leber’s Congenital Amaurosis is Safe and Effective Through 1.5 Years After Vector Administration. Mol Ther 18:643–650
Sullivan JM, Pietras KM, Shin BJ et al (2002) Hammerhead ribozymes designed to cleave all human rod opsin mRNAs which cause autosomal dominant retinitis pigmentosa. Mol Vis 8:102–113
Tam BM, Moritz OL (2006) Characterization of rhodopsin P23H-induced retinal degeneration in a Xenopus laevis model of retinitis pigmentosa. Invest Ophthalmol Vis Sci 47:3234–3241
Tessitore A, Parisi F, Denti MA et al (2006) Preferential silencing of a common dominant rhodopsin mutation does not inhibit retinal degeneration in a transgenic model. Mol Ther 14:692–699
Timmers A, Zhang H, Squitieri A et al (2001) Subretinal injections in rodent eyes: effects on electrophysiology and histology of rat retina. Mol Vis 7:131–137
van Soest S, Westerveld A, de Jong PT et al (1999) Retinitis pigmentosa: defined from a molecular point of view. Surv Ophthalmol 43:321–334
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this paper
Cite this paper
Mao, H., Gorbatyuk, M.S., Hauswirth, W.W., Lewin, A.S. (2012). Gene Delivery of Wild-Type Rhodopsin Rescues Retinal Function in an Autosomal Dominant Retinitis Pigmentosa Mouse Model. In: LaVail, M., Ash, J., Anderson, R., Hollyfield, J., Grimm, C. (eds) Retinal Degenerative Diseases. Advances in Experimental Medicine and Biology, vol 723. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-0631-0_27
Download citation
DOI: https://doi.org/10.1007/978-1-4614-0631-0_27
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4614-0630-3
Online ISBN: 978-1-4614-0631-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)